- FDA expanded Olumiant (baricitinib) for severe alopecia areata to children 12 years and older, based on 36-week data from the phase 3 BRAVE-AA-PEDS adolescent cohort.
- Foundayo is a once-daily oral small-molecule GLP-1 taken without food or water restrictions; phase 3 ATTAIN-1 showed average weight reductions of 7.4% to 11.1% at 72 weeks depending on dose.
- Foundayo booked $98 million in Q2 2026, its first full quarter, while Eli Lilly held 60.9% of the US obesity and diabetes drug market versus Novo Nordisk's 38.8%.
- Medicare began covering obesity drugs in July 2026, expanding the addressable patient population for oral GLP-1 therapies.
- Eli Lilly broke ground on a $6.5 billion Houston manufacturing facility expected operational by 2030, part of a $27 billion US commitment since February 2025.
Quotes
“One-third of all new patients starting an oral GLP-1 medication are now choosing Foundayo.”
“And that market share is growing week over week”